AlgoNomics to enter research collaboration with Genmab

Belgian biotech company AlgoNomics has entered into a research collaboration with Genmab, in which it will employ its antibody structure database and Tripole technology to assist Genmab in research related to the structural analysis of Genmab's proprietary antibody scaffolds, including the UniBody technology.

The research collaboration focuses on the structural properties of fully human antibody and UniBody molecules. Detailed analysis of such structural properties can provide novel insights into their specific function or therapeutic activity. By combining experimental observations with such analyses from AlgoNomics Tripole technology and antibody structure database, the companies hope it may be possible to further improve on the properties of these antibodies.

Tripole is a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions. Focusing on therapeutic antibodies and antibody-based proteins, AlgoNomics has developed an in-house, annotated database of structurally aligned antibody domains enabling novel applications in the antibody engineering field.

Under the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. Other financial details and the therapeutic focus of the collaboration were not disclosed.